Cite
The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
MLA
Arnold Péter Ráduly, et al. “The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications.” International Journal of Molecular Sciences, vol. 24, no. 1, Dec. 2022, p. 446. EBSCOhost, https://doi.org/10.3390/ijms24010446.
APA
Arnold Péter Ráduly, Fruzsina Sárkány, Máté Balázs Kovács, Brigitta Bernát, Béla Juhász, Zoltán Szilvássy, Róbert Porszász, Balázs Horváth, Norbert Szentandrássy, Péter Nánási, Zoltán Csanádi, István Édes, Attila Tóth, Zoltán Papp, Dániel Priksz, & Attila Borbély. (2022). The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications. International Journal of Molecular Sciences, 24(1), 446. https://doi.org/10.3390/ijms24010446
Chicago
Arnold Péter Ráduly, Fruzsina Sárkány, Máté Balázs Kovács, Brigitta Bernát, Béla Juhász, Zoltán Szilvássy, Róbert Porszász, et al. 2022. “The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications.” International Journal of Molecular Sciences 24 (1): 446. doi:10.3390/ijms24010446.